Omkar Pharmachem Intrinsic Value
Omkar Pharmachem intrinsic value. Omkar Pharmachem (OMKARPH) median intrinsic value is ₹3.06 from 5 valuation models (range ₹3–₹25), vs current price ₹10.19 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read OMKARPH dividend growth for the complete payout history and dividend yield track record.
OMKARPH Valuation Methods Summary — DCF, Graham Number & P/E
Omkar Pharmachem intrinsic value across 5 models vs current price ₹10.19 — upside/downside and value range per method. For current market price and key ratios, visit Omkar Pharmachem stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3.06 | ₹2.45 - ₹3.67 | -70.0% | EPS: ₹0.10, Sector P/E: 12x |
| Book Value Method | asset | ₹25.47 | ₹22.92 - ₹28.02 | +150.0% | Book Value/Share: ₹37.00, P/B: 1.0x |
| PEG Ratio Method | growth | ₹3.06 | ₹2.75 - ₹3.37 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹3.06 | ₹2.75 - ₹3.37 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹9.12 | ₹8.21 - ₹10.03 | -10.5% | EPS: ₹0.10, BVPS: ₹37.00 |
OMKARPH Intrinsic Value vs Market Price — All Valuation Models
Omkar Pharmachem fair value range ₹3–₹25 vs current market price ₹10.19 across 5 valuation models. Compare with OMKARPH fair price to assess whether the stock is under or overvalued.
OMKARPH Intrinsic Value Analysis — Undervalued or Overvalued?
Omkar Pharmachem median intrinsic value ₹3.06, current price ₹10.19 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of OMKARPH?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Omkar Pharmachem (OMKARPH) is ₹3.06 (median value). With the current market price of ₹10.19, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹3.06 to ₹25.47, indicating ₹3.06 - ₹25.47.
Is OMKARPH undervalued or overvalued?
Based on our multi-method analysis, Omkar Pharmachem (OMKARPH) appears to be trading above calculated value by approximately 70.0%.
OMKARPH Cash Flow Quality — Operating & Free Cash Flow
Omkar Pharmachem operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |